摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(7-bromo-imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol | 425379-12-0

中文名称
——
中文别名
——
英文名称
2-(7-bromo-imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol
英文别名
2-(7-Bromoimidazo[1,2-b][1,2,4]triazin-3-yl)propan-2-ol
2-(7-bromo-imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol化学式
CAS
425379-12-0
化学式
C8H9BrN4O
mdl
——
分子量
257.09
InChiKey
LULRIZCPZCLJCT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    63.3
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(7-bromo-imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol 、 3'-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-2',6,6'-trifluoro-[1,1'-biphenyl]-2-carbonitrile 在 四(三苯基膦)钯 sodium carbonate 作用下, 以 乙二醇二甲醚 为溶剂, 反应 18.0h, 以46%的产率得到3'-[3-(1-hydroxy-1-methylethyl)imidazo[1,2-b][1,2,4]triazin-7-yl]-6,2',6'-trifluorobiphenyl-2-carbonitrile
    参考文献:
    名称:
    [EN] IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
    [FR] DERIVES D'IMIDAZO-TRIAZINE UTILISES EN TANT QUE LIGANDS DES RECEPTEURS GABA
    摘要:
    一类7-苯基咪唑并[1,2-b][1,2,4]三嗪衍生物,其在苯环的间位被一个可选择取代的芳基或杂环芳基基团取代,该基团直接连接或通过氧原子或-NH-键连接,且在苯环上被本文所定义的一个或两个进一步取代基所取代,作为GABAA受体的选择性配体,特别具有对其α2和/或α3和/或α5亚基有良好亲和力,因此对于治疗和/或预防中枢神经系统的不良状况,包括焦虑、抽搐和认知障碍具有益处。
    公开号:
    WO2003093272A1
  • 作为产物:
    描述:
    2-咪唑并[1,2-B][1,2,4]三嗪-7-丙烷-2-醇sodium acetate溶剂黄146 作用下, 反应 0.42h, 以77%的产率得到2-(7-bromo-imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol
    参考文献:
    名称:
    [EN] IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
    [FR] UTILISATION DE DERIVES D'IMIDAZO-TRIAZINE COMME LIGANDS DES RECEPTEURS GABA
    摘要:
    一类咪唑[1,2b][1,2,4]三嗪衍生物,通过在7位被一个可选择取代的五元或六元杂芳环取代,作为GABAA受体的选择性配体,特别对其α2和/或α3和/或α5亚基具有良好的亲和力,因此在治疗和/或预防中枢神经系统的不良症状,包括焦虑、抽搐和认知障碍方面具有益处。
    公开号:
    WO2003093273A1
点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS<br/>[FR] UTILISATION DE DERIVES D'IMIDAZO-TRIAZINE COMME LIGANDS DES RECEPTEURS GABA
    申请人:MERCK SHARP & DOHME
    公开号:WO2003093273A1
    公开(公告)日:2003-11-13
    A class of imidazo[1,2b][1,2,4]triazine derivatives, substituted at the 7-position by an optionally substituted five-membered or six-membered heteroaromatic ring, being selective ligands for GABAA receptors, in particular having good affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    一类咪唑[1,2b][1,2,4]三嗪衍生物,通过在7位被一个可选择取代的五元或六元杂芳环取代,作为GABAA受体的选择性配体,特别对其α2和/或α3和/或α5亚基具有良好的亲和力,因此在治疗和/或预防中枢神经系统的不良症状,包括焦虑、抽搐和认知障碍方面具有益处。
  • Imidazo-triazine derivatives as ligands for GABA receptors
    申请人:——
    公开号:US20030055060A1
    公开(公告)日:2003-03-20
    A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by a (cyano)(fluoro)phenyl moiety, being selective ligands for GABA A receptors, in particular having good affinity for the &agr;2 and/or &agr;3 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety and convulsions.
    一类7-苯基咪唑[1,2-b][1,2,4]三嗪衍生物,通过在苯环的间位上取代(氰基)(氟基)苯基基团,作为GABA受体的选择性配体,特别是对其α2和/或α3亚基具有良好的亲和力,因此对于治疗和/或预防中枢神经系统的不良症状,包括焦虑和惊厥,具有益处。
  • Imidazo-triazine derivatives as ligands for gaba receptors
    申请人:Bettati Michela
    公开号:US20050165023A1
    公开(公告)日:2005-07-28
    A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, and substituted on the phenyl ring by one or two further substituents as defined herein, being selective ligands for GABA A receptors, in particular having good affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    一类7-苯基咪唑[1,2-b][1,2,4]三嗪衍生物,苯环的间位被一个可选择取代的芳基或杂环芳基基团取代,该基团直接连接或由氧原子或-NH-键桥接,并在苯环上进一步取代一个或两个定义如下的取代基,是选择性的GABAA受体配体,特别是对其中的α2和/或α3和/或α5亚基具有良好的亲和力,因此对于治疗和/或预防中枢神经系统不良症状,包括焦虑、惊厥和认知障碍具有益处。
  • Imidazo[1,2-b][1,2,4]triazines as α2/α3 subtype selective GABAA agonists for the treatment of anxiety
    作者:Andrew S.R. Jennings、Richard T. Lewis、Michael G.N. Russell、David J. Hallett、Leslie J. Street、José L. Castro、John R. Atack、Susan M. Cook、Rachael Lincoln、Joanna Stanley、Alison J. Smith、David S. Reynolds、Bindi Sohal、Andrew Pike、George R. Marshall、Keith A. Wafford、Wayne F.A. Sheppard、Spencer J. Tye
    DOI:10.1016/j.bmcl.2005.12.044
    日期:2006.3
    Imidazo[1,2-a]pyrimidines and imidazo[1,2-b][1,2,4]triazines are ligands for the benzodiazepine binding site of GABA(A) receptors that are functionally selective for the alpha 2/alpha 3 subtypes over the alpha 1 subtype. SAR studies to optimise this functional selectivity, pharmacokinetic and behavioural data are described. (C) 2006 Elsevier Ltd. All rights reserved.
  • IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
    申请人:MERCK SHARP & DOHME LTD.
    公开号:EP1343788B1
    公开(公告)日:2005-11-23
查看更多

同类化合物

咪唑并[1,2-b][1,2,4]三唑并[4,3-D][1,2,4]三嗪 3-甲基咪唑并[1,2-b][1,2,4]噻嗪 3-溴-7-甲基咪唑并[1,2-b][1,2,4]三嗪 3-(三氟甲基)咪唑并[1,2-b][1,2,4]三嗪 2-咪唑并[1,2-B][1,2,4]三嗪-7-丙烷-2-醇 2-(3-溴咪唑并[1,2-b][1,2,4]-7-三嗪)丙烷-2-醇 3-(3-methylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine 2-imidazo[1,2-b][1,2,4]triazin-3-ylpropan-2-ol hydrochloride 2,2'-(7,7'-biimidazo[1,2-b][1,2,4]triazine-3,3'-diyl)dipropan-2-ol 2-(2,4-difluorophenyl)-6-((pyridin-2-yloxy)methyl)imidazo[1,2-b][1,2,4]triazine 2-(4-fluorophenyl)-7-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,2-b]-[1,2,4]-triazine 7-Bromo-2-methylimidazo[1,2-b][1,2,4]triazine 1,2,3,4-tetrahydro-dibenzo[4,5:e]imidazo[1,2-b][1,2,4]triazine 2-(7-bromo-imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol imidazo[1,2-b][1,2,4]triazine-6-carboxylic acid ethyl ester 2-(imidazo[1,2-b][1,2,4]triazin-6-yl)ethanol 2-(4-fluorophenyl)-7-(4-methoxybenzyl)imidazo[1,2-b][1,2,4]triazine 7,9-Dimethylimidazo[1,2-b][1,2,4]benzotriazine 7-Methylimidazo[1,2-b][1,2,4]benzotriazine 7-Methoxyimidazo[1,2-b][1,2,4]benzotriazine imidazo[1,2-b][1,2,4]triazine-6-carbaldehyde 3-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-b][1,2,4]triazin-7-amine 7-nitro-3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine Imidazo[1,2-b][1,2,4]triazin-2(1H)-one 6-(3-Methoxycyclohexyl)-2-phenylimidazo[1,2-b][1,2,4]triazine 3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine 2,3-diphenyl-6-thiophen-2-yl-imidazo[1,2-b][1,2,4]triazine 7-(2-chloropyridin-4-yl)-3-trifluoromethylimidazo[1,2-b][1,2,4]triazine 3-(1-fluoro-1-methylethyl)imidazo[1,2-b][1,2,4]triazine 7-[(3,4-dihydroxyphenyl)methylidene]-3-methyl-2-methylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one 6-(5-Chlorothiophen-2-yl)-2,3-dimethylimidazo[1,2-b][1,2,4]triazine 6-(5-Bromothiophen-2-yl)-2,3-dipyridin-2-ylimidazo[1,2-b][1,2,4]triazine 7-[(3,4-dihydroxyphenyl)methylidene]-3-ethyl-2-ethylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one 2-(5-{7-[2-(difluoromethoxy)benzyl]-6-methylimidazo[1,2-b][1,2,4]triazin-2-yl}-pyrimidin-2-yl)propan-2-ol 2-[2-Chloro-4-[2-[2-cyclopentyl-5-(imidazo[1,2-b][1,2,4]triazin-6-ylmethyl)-4,6-dioxooxan-2-yl]ethyl]phenyl]-2-methylpropanenitrile (7E)-3-methyl-2-methylidene-7-[(2,3,4-trimethoxyphenyl)methylidene]-1H-imidazo[1,2-b][1,2,4]triazin-6-one (3E)-3-[(2-chloro-6-fluorophenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (3Z)-3-[(3-methoxyphenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12Z)-12-[(2,4-dichlorophenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (12E)-12-[(4-chlorophenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (3E)-3-(thiophen-2-ylmethylidene)-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12E)-12-[[4-(dimethylamino)phenyl]methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (7E)-7-[(2-methoxyphenyl)methylidene]-3-methyl-2-methylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one (3E)-3-[(3,4-dihydroxyphenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12E)-12-[(3,4,5-trimethoxyphenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (12E)-12-[(2-methoxyphenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one 2-(Azepan-1-yl)-3-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-b][1,2,4]triazine 4-[(11-Hydroxy-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,7,9,11-tetraen-12-yl)methylidene]-2-methoxycyclohexa-2,5-dien-1-one 2-(1-Adamantyl)-6,7,8,9-tetrahydroimidazo[1,2-b][1,2,4]benzotriazine 6-[1-(Furan-2-ylmethyl)-2,5-dimethylpyrrol-3-yl]-2,3-diphenylimidazo[1,2-b][1,2,4]triazine